Nadim Ahmed - 18 Feb 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Reporting relationship: President and CEO, Director
Issuer ticker: CGEM
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 17:00:08 UTC
Prior SEC filing: 29 Dec 2025
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer, Attorney-in-Fact

Key filing fact

Nadim Ahmed filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 19 Feb 2026.

Key facts

This page summarizes Nadim Ahmed's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 17:00.

Change

Previous filing in this sequence was filed on 29 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001731193 Primary reporting owner

AHMED NADIM

Relationship: President and CEO, Director
Address: C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE
Signature: /s/ Jacquelyn Sumer, Attorney-in-Fact
Signature date: 19 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +828,000
Change %
Price: $0.000000
Shares after: 828,000
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 828,000
Exercise price: $12.44
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.